These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 28416503)

  • 1. Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells.
    Du J; Paz K; Thangavelu G; Schneidawind D; Baker J; Flynn R; Duramad O; Feser C; Panoskaltsis-Mortari A; Negrin RS; Blazar BR
    Blood; 2017 Jun; 129(23):3121-3125. PubMed ID: 28416503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner.
    McDonald-Hyman C; Flynn R; Panoskaltsis-Mortari A; Peterson N; MacDonald KP; Hill GR; Luznik L; Serody JS; Murphy WJ; Maillard I; Munn DH; Turka LA; Koreth J; Cutler CS; Soiffer RJ; Antin JH; Ritz J; Blazar BR
    Blood; 2016 Aug; 128(7):1013-7. PubMed ID: 27385791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor Treg expansion by liposomal α-galactosylceramide modulates Tfh cells and prevents sclerodermatous chronic graft-versus-host disease.
    Sugiura H; Matsuoka KI; Fukumi T; Sumii Y; Kondo T; Ikegawa S; Meguri Y; Iwamoto M; Sando Y; Nakamura M; Toji T; Ishii Y; Maeda Y
    Immun Inflamm Dis; 2021 Sep; 9(3):721-733. PubMed ID: 33942544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality.
    Schneidawind D; Baker J; Pierini A; Buechele C; Luong RH; Meyer EH; Negrin RS
    Blood; 2015 May; 125(22):3491-500. PubMed ID: 25795920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells.
    Schneidawind D; Pierini A; Alvarez M; Pan Y; Baker J; Buechele C; Luong RH; Meyer EH; Negrin RS
    Blood; 2014 Nov; 124(22):3320-8. PubMed ID: 25293774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote
    Jahnke S; Schmid H; Secker KA; Einhaus J; Duerr-Stoerzer S; Keppeler H; Schober-Melms I; Baur R; Schumm M; Handgretinger R; Bethge W; Kanz L; Schneidawind C; Schneidawind D
    Front Immunol; 2019; 10():1542. PubMed ID: 31354710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease.
    Paz K; Flynn R; Du J; Tannheimer S; Johnson AJ; Dong S; Stark AK; Okkenhaug K; Panoskaltsis-Mortari A; Sage PT; Sharpe AH; Luznik L; Ritz J; Soiffer RJ; Cutler CS; Koreth J; Antin JH; Miklos DB; MacDonald KP; Hill GR; Maillard I; Serody JS; Murphy WJ; Munn DH; Feser C; Zaiken M; Vanhaesebroeck B; Turka LA; Byrd JC; Blazar BR
    Am J Transplant; 2019 Jun; 19(6):1820-1830. PubMed ID: 30748099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of natural killer T cells enhances the function of regulatory T-cell therapy in suppressing murine GVHD.
    Hirai T; Lin PY; Simonetta F; Maas-Bauer K; Turkoz M; Mavers M; Baker J; Negrin RS
    Blood Adv; 2021 Jun; 5(11):2528-2538. PubMed ID: 34100904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice.
    Wu Y; Schutt S; Paz K; Zhang M; Flynn RP; Bastian D; Sofi MH; Nguyen H; Dai M; Liu C; Chang YJ; Blazar BR; Yu XZ
    Blood; 2018 Apr; 131(17):1974-1986. PubMed ID: 29530952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corruption of dendritic cell antigen presentation during acute GVHD leads to regulatory T-cell failure and chronic GVHD.
    Leveque-El Mouttie L; Koyama M; Le Texier L; Markey KA; Cheong M; Kuns RD; Lineburg KE; Teal BE; Alexander KA; Clouston AD; Blazar BR; Hill GR; MacDonald KP
    Blood; 2016 Aug; 128(6):794-804. PubMed ID: 27338097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant germinal center formation, follicular T-helper cells, and germinal center B-cells were involved in chronic graft-versus-host disease.
    Shao L; Lie AK; Zhang Y; Wong CH; Kwong YL
    Ann Hematol; 2015 Sep; 94(9):1493-504. PubMed ID: 25963280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-Y Aggravates Murine Chronic Graft-
    Wan L; Jin Z; Hu B; Lv K; Lei L; Liu Y; Song Y; Zhu Y; Gong H; Xu M; Du Y; Xu Y; Liu H; Wu D; Liu Y
    Front Immunol; 2020; 11():559740. PubMed ID: 33329519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extrafollicular CD4
    Deng R; Hurtz C; Song Q; Yue C; Xiao G; Yu H; Wu X; Muschen M; Forman S; Martin PJ; Zeng D
    Nat Commun; 2017 Oct; 8(1):978. PubMed ID: 29042531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host-residual invariant NK T cells attenuate graft-versus-host immunity.
    Haraguchi K; Takahashi T; Matsumoto A; Asai T; Kanda Y; Kurokawa M; Ogawa S; Oda H; Taniguchi M; Hirai H; Chiba S
    J Immunol; 2005 Jul; 175(2):1320-8. PubMed ID: 16002737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease.
    Fransolet G; Ehx G; Somja J; Delens L; Hannon M; Muller J; Dubois S; Drion P; Caers J; Humblet-Baron S; Delvenne P; Beguin Y; Conteduca G; Baron F
    J Hematol Oncol; 2016 Jul; 9(1):53. PubMed ID: 27377819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GM-CSF therapy inhibits chronic graft-versus-host disease via expansion of regulatory T cells.
    Hotta M; Yoshimura H; Satake A; Tsubokura Y; Ito T; Nomura S
    Eur J Immunol; 2019 Jan; 49(1):179-191. PubMed ID: 30457669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease.
    Le Huu D; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Fujimoto M
    J Invest Dermatol; 2012 Dec; 132(12):2752-61. PubMed ID: 22810302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease.
    Kim BS; Nishikii H; Baker J; Pierini A; Schneidawind D; Pan Y; Beilhack A; Park CG; Negrin RS
    Blood; 2015 Jul; 126(4):546-57. PubMed ID: 26063163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Foxp3
    Chen YB; Efebera YA; Johnston L; Ball ED; Avigan D; Lekakis LJ; Bachier CR; Martin P; Duramad O; Ishii Y; Han S; Jung YJ; Lee D; Kunkel L; Negrin RS; Bui JD
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):625-634. PubMed ID: 28104514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.